156 related articles for article (PubMed ID: 16487015)
1. Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure.
Collins BJ; Schneider AB; Prinz RA; Xu X
Thyroid; 2006 Jan; 16(1):61-6. PubMed ID: 16487015
[TBL] [Abstract][Full Text] [Related]
2. Radiation induced thyroid cancer: fundamental and applied aspects.
Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
[TBL] [Abstract][Full Text] [Related]
3. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
Takahashi K; Eguchi H; Arihiro K; Ito R; Koyama K; Soda M; Cologne J; Hayashi Y; Nakata Y; Nakachi K; Hamatani K
Mol Carcinog; 2007 Mar; 46(3):242-8. PubMed ID: 17186541
[TBL] [Abstract][Full Text] [Related]
4. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE
Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515
[TBL] [Abstract][Full Text] [Related]
5. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
Sapio MR; Posca D; Troncone G; Pettinato G; Palombini L; Rossi G; Fenzi G; Vitale M
Eur J Endocrinol; 2006 Feb; 154(2):341-8. PubMed ID: 16452550
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas.
Lima J; Trovisco V; Soares P; Máximo V; Magalhães J; Salvatore G; Santoro M; Bogdanova T; Tronko M; Abrosimov A; Jeremiah S; Thomas G; Williams D; Sobrinho-Simões M
J Clin Endocrinol Metab; 2004 Sep; 89(9):4267-71. PubMed ID: 15356020
[TBL] [Abstract][Full Text] [Related]
7. BRAF T1796A transversion mutation in various thyroid neoplasms.
Xing M; Vasko V; Tallini G; Larin A; Wu G; Udelsman R; Ringel MD; Ladenson PW; Sidransky D
J Clin Endocrinol Metab; 2004 Mar; 89(3):1365-8. PubMed ID: 15001635
[TBL] [Abstract][Full Text] [Related]
8. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
9. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
[TBL] [Abstract][Full Text] [Related]
10. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure.
Powell N; Jeremiah S; Morishita M; Dudley E; Bethel J; Bogdanova T; Tronko M; Thomas G
J Pathol; 2005 Apr; 205(5):558-64. PubMed ID: 15714593
[TBL] [Abstract][Full Text] [Related]
11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
12. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas.
Kumagai A; Namba H; Saenko VA; Ashizawa K; Ohtsuru A; Ito M; Ishikawa N; Sugino K; Ito K; Jeremiah S; Thomas GA; Bogdanova TI; Tronko MD; Nagayasu T; Shibata Y; Yamashita S
J Clin Endocrinol Metab; 2004 Sep; 89(9):4280-4. PubMed ID: 15356022
[TBL] [Abstract][Full Text] [Related]
15. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.
Cradic KW; Milosevic D; Rosenberg AM; Erickson LA; McIver B; Grebe SK
J Clin Endocrinol Metab; 2009 Dec; 94(12):5001-9. PubMed ID: 19850689
[TBL] [Abstract][Full Text] [Related]
16. ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma.
Smyth P; Finn S; Cahill S; O'Regan E; Flavin R; O'Leary JJ; Sheils O
Int J Surg Pathol; 2005 Jan; 13(1):1-8. PubMed ID: 15735849
[TBL] [Abstract][Full Text] [Related]
17. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
18. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci.
Park SY; Park YJ; Lee YJ; Lee HS; Choi SH; Choe G; Jang HC; Park SH; Park DJ; Cho BY
Cancer; 2006 Oct; 107(8):1831-8. PubMed ID: 16983703
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer.
Efanov AA; Brenner AV; Bogdanova TI; Kelly LM; Liu P; Little MP; Wald AI; Hatch M; Zurnadzy LY; Nikiforova MN; Drozdovitch V; Leeman-Neill R; Mabuchi K; Tronko MD; Chanock SJ; Nikiforov YE
J Natl Cancer Inst; 2018 Apr; 110(4):371-378. PubMed ID: 29165687
[TBL] [Abstract][Full Text] [Related]
20. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy.
Nakashima M; Takamura N; Namba H; Saenko V; Meirmanov S; Matsumoto N; Hayashi T; Maeda S; Sekine I
Hum Pathol; 2007 Apr; 38(4):621-8. PubMed ID: 17270245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
